A Retrospective Comparative Study of SIRT and
CS-PHP for Liver Targeted Therapy of Patients with Metastatic Uveal
Melanoma
NEW
YORK, Aug. 29, 2023 /PRNewswire/ -- Delcath
Systems, Inc. (Nasdaq: DCTH), an interventional oncology company
focused on the treatment of primary and metastatic cancers of the
liver, today announced an oral presentation by independent
investigators at the Cardiovascular and Interventional Radiological
Society of Europe (CIRSE) Annual
Meeting to be held in Copenhagen,
Denmark from September 9-13,
2023.
CIRSE Presentation Details:
Title: Selective internal radiotherapy (SIRT) and
chemosaturation-percutaneous hepatic perfusion (CS-PHP) for
metastasized uveal melanoma: a retrospective comparative study
Type: Scientific Paper Session
Session: Advanced IO techniques: pushing the bar in IO
Presenters: Professor Dr. med. Gerd
Grozinger, University Clinical Center Tubingen, Germany
Presentation Number: 176.5
Date and Time: 9 Sep 2023 17:30–18:30 (CET)
The authors will discuss results from a retrospective
comparative study of SIRT and CS-PHP utilizing
CHEMOSAT® for liver targeted therapy of patients
with metastasized uveal melanoma.
The full CIRSE meeting program is available
at: https://cirsecongress.cirse.org/.
About Delcath Systems, Inc.
Delcath Systems, Inc. is an interventional oncology company
focused on the treatment of primary and metastatic liver cancers.
The Company's proprietary products, HEPZATO KIT™ (melphalan for
Injection/Hepatic Delivery System), approved for use in
the United States by the Food and
Drug Administration, and CHEMOSAT Hepatic Delivery System for
Melphalan percutaneous hepatic perfusion (PHP), designated under
the medical device regulation for use in Europe and the United Kingdom, are designed to administer
high-dose chemotherapy to the liver while controlling systemic
exposure and associated side effects during a PHP procedure. For
more information regarding HEPZATO KIT and its use, including
Important Safety Information and Boxed Warning, please visit
HEPZATOKIT.com. For more information regarding CHEMOSAT and
its use, please visit Chemosat.com.
Contact:
Investor Relations Contact:
Ben Shamsian
Lytham Partners
646-829-9701
shamsian@lythampartners.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/delcath-systems-announces-an-independent-investigator-presentation-at-the-cardiovascular-and-interventional-radiological-society-of-europe-cirse-annual-meeting-301911900.html
SOURCE Delcath Systems, Inc.